Clinical Trials Search at Vanderbilt-Ingram Cancer Center
M7824 Versus Pembrolizumab as a First-line (1L) Treatment in Participants With Programmed Death-ligand 1 (PD-L1) Expressing Advanced Non-small Cell Lung Cancer (NSCLC)
The study will evaluate M7824 monotherapy versus pembrolizumab as 1L treatment for participants with advanced NSCLC with high PD-L1-tumor expression.
Not Available
II
Iams, Wade
NCT03631706
VICCTHO18139
Study of Avelumab-M3814 Combinations
The main purpose of the study is to evaluate a safe, tolerable recommended Phase II dose (RP2D) and / or the maximum tolerated dose (MTD) of M3814 when given in combination with avelumab with and without radiotherapy in participants with selected advanced solid tumors.
Not Available
I
Iams, Wade
NCT03724890
VICCPHI18160
Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy
This is a Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center, International Study of Durvalumab or Durvalumab and Tremelimumab as Consolidation Treatment for Patients with LS-SCLC Who Have Not Progressed Following Concurrent Chemoradiation Therapy
Not Available
III
Iams, Wade
NCT03703297
VICCTHO1901
Individual Patient Program for Selinexor Monotherapy in Docetaxel Contraindicated KRAS-Positive Malignancy
Not Available
N/A
Iams, Wade
VICCTHO19136
